POET2 registry: Comparison of annual direct medical costs of treating type 2 diabetes after addition of insulin NPH or insulin glargine to oral antidiabetic therapy in the Czech Republic

Česká verzia

Authors: Milan Kvapil ¹; Denisa Janíčková Žďárská ¹; Josef Suchopár ²; Michal Prokeš ²; Jan Brož ¹
Authors place of work: Interní klinika 2. LF UK a FN Motol Praha, přednosta prof. MUDr. Milan Kvapil, CSc., MBA ¹; Infopharm Praha, a. s., předseda představenstva PharmDr. Josef Suchopár ²
Published in the journal: Vnitř Lék 2015; 61(1): 24-32
Category: Original Contributions

Summary

Introduction:
Poor glycemic control and the resulting development of complications of type 2 diabetes (DM2T) increase treatment costs. If adequate glycemic control cannot be achieved by lifestyle modifications and oral antidiabetic (OAD) therapy, initiation of insulin therapy is recommended. Cost effectiveness of basal insulins of the type NPH or glargine in combination with OAD for the treatment of DM2T was examined in a number of pharmacoeconomic studies. However, none of these studies were conducted in the Czech Republic. Therefore, the aim of the project POET2 was to compare annual direct medical costs of treating DM2T after addition of insulin NPH or glargine to OAD therapy in a clinical practice setting in the Czech Republic.

Methodology:
Data collected from 1 967 patients who met the criteria for inclusion into the non-interventional prospective registry POET2 (DM2T, ongoing OAD therapy, glycated hemoglobin HbA_1c > 6 % IFCC) and who were observed for 12 months following the start of insulin therapy (glargine: n = 1 061 vs NPH: n = 906) were analysed. Costs of treatment were analysed from the perspective of health insurance companies and included costs of medication, medical devices and medical procedures.

Results:
In both treatment groups a reduction of HbA_1c (glargine group: by 1.77 % IFCC vs NPH group: by 1.73 % IFCC) and fasting plasma glucose (glargine group: by 3.67 mmol/l vs NPH group: by 3.63 mmol/l) was observed. Insulin glargine therapy was associated with the incidence of a significantly lower number of documented symptomatic hypoglycemic events (glargine group: 0.840 events per patient and year of treatment vs. NPH group: 1.053 events per patient and year of treatment; p < 0.05). Overall annual direct medical costs associated with the initiation of basal insulin treatment were higher on average by 2547.07 CZK among patients treated with insulin glargine (glargine group: 12 173.09 ± 4 169.44 CZK vs NPH group: 9 626.02 ± 3 432.79 CZK; p < 0.001) due to higher costs of medication (glargine group: 7 992.97 ± 4 001.81 CZK vs NPH group: 3 784.2 ± 3 181.48 CZK; p < 0.001). By contrast, costs of medical devices (glargine group: 2 332.08 ± 917.84 CZK vs NPH group: 3 893.95 ± 989.79 CZK; p < 0.001) and medical procedures (glargine group: 1 848.04 ± 684.89 CZK vs NPH group: 1 947.87 ± 685.43 CZK; p < 0.001) were lower among patients treated with insulin glargine.

Conclusion:
Addition of basal insulin to OAD therapy was an efficacious therapeutic intervention for the treatment of DM2T in a clinical practice setting in the Czech Republic. Overall annual direct medical costs were higher among patients treated with insulin glargine than among patients treated with insulin NPH. However, costs of medical devices and medical procedures were lower in the insulin glargine group. In addition, incidence of hypoglycemia was significantly lower among patients treated with insulin glargine.

Key words:
direct yearly healthcare costs – insulin glargine – insulin NPH –- type 2 diabetes mellitus

Zdroje

1. Zvolský M. Činnost oboru diabetologie, péče o diabetiky v roce 2012. ÚZIS ČR. Aktuální informace 2013; 24. Dostupné z WWW: <http://www.uzis.cz/rychle-informace/cinnost-oboru-diabetologie-pece-diabetiky-roce-2012>.

2. Doležal T, Písaříková Z, Zemanová P et al. Náklady na diabetes 2. typu v podmínkách zdravotního systému České republiky. Vnitř Lék 2009; 55(4): 342–344.

3. Ettaro L, Songer TJ, Zhang P et al. Cost-of-illness studies in diabetes mellitus. Pharmacoeconomics 2004; 22(3): 149–164.

4. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321(7258): 405–412.

5. Calles-Escandón J, Lovato LC, Simons-Morton DG et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010; 33(4): 721–727.

6. Bonds DE, Miller ME, Bergenstal RM et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010; 340: b4909. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.b4909>.

7. McCoy RG, Van Houten HK, Ziegenfuss JY et al. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 2012; 35(9): 1897–1900.

8. Chow E, Bernjak A, Williams S et al. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes 2014; 63(5): 1738–1747.

9. Doporučený postup péče o diabetes mellitus 2. typu – aktualizace 2012. Česká diabetologická společnost 2012. Dostupné z WWW: <http://www.diab.cz/dokumenty/dm2_2011.pdf>.

10. Riddle MC, Rosenstock J, Gerich J et al. Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26(11): 3080–3086.

11. Home PD, Fritsche A, Schinzel S et al. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. Diabetes Obes Metab 2010; 12(9): 772–779.

12. Mullins P, Sharplin P, Yki-Jarvinen H et al. Negative binoval meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 2007; 29(8): 1607–1619.

13. Warren E, Weatherley-Jones E, Chilcott J et al. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess 2004; 8(45): iii, 1–57.

14. Brändle M, Azoulay M, Greiner RA. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland. Int J Clin Pharmacol Ther 2007; 45(4): 203–220.

15. Grima DT, Thompson MF, Sauriol L. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada. Pharmacoeconomics 2007; 25(3): 253–266.

16. Levin P. The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics. Diabetes Obes Metab 2008; 10(Suppl 2): 66–75.

17. Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes mellitus. CMAJ 2009; 180(4): 400–407.

18. Xie L, Wei W, Pan C et al. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies. J Med Econ 2013; 16(9): 1137–1145.

19. Miller DR, Gardner JA, Hendricks AM et al. Health care resource utilization and expenditures associated with the use of insulin glargine. Clin Ther 2007; 29(3): 478–487.

20. Schöffski O, Breitscheidel L, Benter U et al. Resource utilization and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study. J Med Econ 2008; 11(4): 695–712.

21. Kruntorádová K, Suchánková E, Klimeš J et al. Náklady na hypoglykemické stavy u pacientů s diabetes mellitus: cost-of-illness studie. Farmakoekonomika 2012; 6(1): 17–21.

22. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010; 33(6): 1389–1394.